Parkinson's UK

Parkinson's UK is a charity dedicated to supporting individuals affected by Parkinson's disease and advancing research in the field. The organization focuses on providing crucial information, resources, and support to those living with the condition, as well as their families and caregivers. By funding innovative research initiatives, Parkinson's UK aims to improve treatment options and ultimately find a cure for the disease. Through various programs and community engagement, the charity works to raise awareness and foster understanding of Parkinson's, ensuring that those impacted have access to the support they need.

Arthur Roach Ph.D

Director of Research

7 past transactions

MISSION Therapeutics

Grant in 2024
MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

Lucy Therapeutics

Venture Round in 2024
Lucy Therapeutics is a biotechnology company focused on developing innovative treatments for neurological diseases by targeting mitochondrial dysfunction. The company employs a unique approach to drug discovery, concentrating on drugging targets linked to the early stages of disease pathogenesis. This methodology not only addresses specific neurological conditions but also has the potential to extend treatment options for other related disorders, such as Parkinson's Disease and Alzheimer's Disease. Additionally, Lucy Therapeutics is dedicated to creating proprietary small molecule therapies and diagnostic biomarkers aimed at enhancing the understanding of the central nervous system. By leveraging advanced genetic technologies, the company aims to provide insights into personalized medicine, thereby improving patient outcomes and enabling more precise healthcare interventions.

Neumora Therapeutics

Grant in 2024
Neumora Therapeutics is a clinical-stage biotechnology company focused on developing precision medicines for brain diseases by combining data science with neuroscience. Founded to address the global brain disease crisis, Neumora takes an innovative approach to treatment development. The company has established a robust therapeutic pipeline that includes seven clinical and preclinical neuroscience programs targeting novel mechanisms of action for various underserved neuropsychiatric and neurodegenerative disorders. Neumora plans to advance its pipeline further by initiating multiple clinical trials across its programs in the upcoming 12 to 18 months.

University of Nottingham

Grant in 2024
The University of Nottingham is a comprehensive, campus-based institution with global reach. It offers high-quality teaching across various disciplines, including business through its renowned Nottingham University Business School. The university is known for its influential research and commitment to internationalisation, providing students with a valuable experience that prepares them for their future careers.

NRG Therapeutics

Seed Round in 2021
Founded in 2018 by industry veterans in neuroscience drug discovery, NRG Therapeutics is a biotechnology company dedicated to developing therapeutic approaches that restore mitochondrial function. Their primary focus is slowing or halting the progression of neurodegenerative diseases like Parkinson's and Alzheimer's through innovative drug discovery.

NRG Therapeutics

Grant in 2019
Founded in 2018 by industry veterans in neuroscience drug discovery, NRG Therapeutics is a biotechnology company dedicated to developing therapeutic approaches that restore mitochondrial function. Their primary focus is slowing or halting the progression of neurodegenerative diseases like Parkinson's and Alzheimer's through innovative drug discovery.

Keapstone Therapeutics

Seed Round in 2018
Founded in 2017, Keapstone Therapeutics is a UK-based biotech company focused on developing drugs targeting the Nrf2 signaling pathway for neurodegenerative diseases such as Parkinson's and Motor Neuron Disease (MND).
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.